Mr. Burge et al., PROLONGED EFFICACY OF SHORT-ACTING INSULIN LISPRO COMBINATION WITH HUMAN ULTRALENTE IN INSULIN-DEPENDENT DIABETES-MELLITUS, The Journal of clinical endocrinology and metabolism, 82(3), 1997, pp. 920-924
Insulin Lispro is a newly FDA approved analog of human insulin that ex
hibits rapid absorption and a short duration of action after sc inject
ion. Although Lispro insulin improves immediate postprandial glycemia
compared to Regular insulin, long term trials of Lispro insulin have n
ot shown improvement in overall glycemic control, as determined by gly
cosylated hemoglobin. We hypothesize that this lack of improvement is
attributable to the development of late postprandial hyperglycemia sec
ondary to a waning of Lispro insulin's effect in conjunction with cont
inued meal absorption. This study was designed to evaluate the duratio
n of Lispro-induced reductions in plasma glucose after a standardized
meal when Lispro insulin is incorporated into a regimen typically empl
oyed in insulin-dependent diabetes mellitus. After establishment of eu
glycemia overnight, 12 healthy IDDM patients received human Ultralente
insulin (0.2 U/kg) alone and in combination with each of the followin
g treatments in random sequence immediately before ingesting a 750-Cal
American Diabetes Association breakfast: 1) 0.15 U/kg human Regular i
nsulin (Regular 0.15 group), 2) 0.15 U/kg Lispro insulin (Lispro 0.15
group), 3) 0.1 U/kg Lispro insulin (Lispro 0.1 group), and 4) an equim
olar (1:1) mixture of Lispro and Regular insulins (0.15 U/kg; 1:1 Mix
group). Glucose and hormonal parameters were assessed for 8 h after th
e meal. Peak postprandial glucose was increased in the Regular insulin
group compared to that in all groups that incorporated Lispro insulin
(P < 0.001). Glucose area under the curve (AUG) was decreased in the
Lispro 0.15 group compared to that in the Lispro 0.1 group, and glucos
e AUC was decreased in the Lispro 0.15 and 1:1 Mix groups compared to
that in the group given Regular insulin (P < 0.001). Mean plasma gluco
se concentrations during the final hour of study were increased in the
Ultralente group compared with those in all other treatment groups an
d were increased in the Lispro 0.1 group compared with those in the Re
gular, Lispro 0.15, and 1:1 Mix groups (P < 0.05). Insulin AUC was sig
nificantly reduced in the Lispro 0.1 group compared to those in all ot
her short acting insulin groups (P < 0.001), and time to peak insulin
was more rapid in the two Lispro groups than those in all other treatm
ent groups (P < 0.01). The glucagon response was significantly greater
in the Ultralente group compared to those with all other treatments.
There was no difference in the development of hypoglycemia between the
groups. This study demonstrates that the reductions in plasma glucose
effected by Lispro insulin are consistent and stable for 8 h after me
al ingestion when Lispro insulin is used in combination with human Ult
ralente insulin. These findings suggest that improvement in overall gl
ycemia, as assessed by glycosylated hemoglobin, may be achievable with
Lispro insulin if adequate doses are administered.